Europe

Henrik Watz, MD, PhD, is the chief investigator and author of trial results for EpiEndo’s clinical trial of glasmacinal (EP395). Results indicated that glasmacinal reduced neutrophilic inflammation in COPD patients without any detectable impact on the lung microbiome, supporting preclinical findings of reduced antimicrobial resistance potential. Dr. Watz in the accompanying press release: “The data … Read more

Velocity Clinical Research, the world’s leading integrated research site organization, has appointed Ines Abs as its new Country Head of Germany, reinforcing its commitment to growth in Europe at a time when other site networks are retreating from the region. Ines brings over two decades of experience in clinical research operations, having held senior leadership … Read more

The U.S. clinical research landscape faces uncertainty. NIH grant cancellations, FDA staffing cuts, and regulatory uncertainty are creating real challenges for the industry’s traditional leader. Europe has an opportunity if it acts decisively. In his latest op-ed for BioSpace, Craig Koch examines why this moment matters for European clinical research. While the EEA’s share of … Read more

Henrik Watz, MD, PhD, has been named a 2024 Top Scholar by ScholarGPS, ranked #34 globally among chronic obstructive pulmonary disease (COPD) researchers over the past five years, and recognized among the top 0.5% of all researchers worldwide. Over the past year, Dr. Watz has: Presented compelling real-world data at ATS 2025 on the long-term … Read more

Henrik Watz, MD, PhD, presented compelling real-world data at the American Thoracic Society Annual Meeting on the long-term impact of dupilumab therapy in patients with severe asthma. Participants in the ProVENT study experienced sustained improvements in lung function, asthma control, and quality of life. Notably, more than half achieved asthma remission within two years of … Read more